Drugs / Hyperpolarized Xenon129
Hyperpolarized Xenon129
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02638519 | Jun 2016 → Apr 2022 | Alzheimer disease | Thunder Bay Regional Health Research Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT07046910 | Apr 2019 → Mar 2029 expected | transplant rejection | University of Virginia | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hyperpolarized Xenon129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07046910 ↗ |
| Modality | Diagnostic / imaging agent | “Lung transplant recipient with hyperpolarized Xe129 in MRI as an inhalation contrast agent” NCT07046910 ↗ |
| Route | Inhaled | “as an inhalation contrast agent” NCT07046910 ↗ |